PGA5 Antibody

What are the key molecular characteristics of PGA5?

PGA5 is characterized by a molecular weight of approximately 42-48 kDa as observed in Western blot analyses . The full-length human PGA5 protein consists of 388 amino acids (Met1-Ala388) . Like other pepsinogens, it has optimal enzymatic activity under acidic pH conditions and is inhibited by pepstatin . The protein shows particularly broad substrate specificity, with a preference for cleaving bonds involving phenylalanine and leucine residues, though it can cleave many other peptide bonds to varying degrees .

PGA5 antibodies are utilized in several research applications:

• Western Blotting (WB): For detection and quantification of PGA5 protein in tissue lysates, particularly from stomach tissue. Most PGA5 antibodies demonstrate a specific band at approximately 42-48 kDa under reducing conditions .

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative measurement of PGA5 in biological samples. Typical dilutions range from 1:10,000 depending on the specific antibody .

• Immunohistochemistry (IHC): For localization and visualization of PGA5 expression in tissue sections, particularly in stomach tissues. This helps in understanding the distribution pattern of the protein in normal and pathological conditions .

• Immunofluorescence (IF): For cellular localization studies, particularly with fluorophore-conjugated antibodies like Alexa Fluor 647 or 750 variants .

What reactivity do PGA5 antibodies typically show across species?

Most commercially available PGA5 antibodies show primary reactivity with human samples . Some antibodies demonstrate cross-reactivity with pig samples as well . While certain polyclonal antibodies may react with mouse and rat samples due to conserved epitopes, species cross-reactivity should be experimentally validated for each specific antibody . When working with non-human samples, it's essential to verify the cross-reactivity of the selected antibody through preliminary testing or by choosing antibodies specifically validated for the species of interest.

How should I optimize Western blot conditions for PGA5 detection?

For optimal PGA5 detection via Western blot:

• Sample preparation: Use RIPA buffer with protease inhibitors for extraction from tissues, particularly stomach tissue. For stomach cancer samples, consider using specialized lysis buffers to account for tissue heterogeneity .

• Protein loading: Load 20-50 μg of total protein per lane. For stomach tissue lysates, 0.2 mg/mL concentration has been validated in published protocols .

• Separation conditions: Use reducing conditions and standard SDS-PAGE (10-12% gels) for optimal separation. A 42-48 kDa band is expected for PGA5 .

• Transfer: PVDF membranes are recommended for efficient protein transfer and reduced background .

• Antibody concentrations: Primary antibody concentrations range from 0.1-5 μg/mL depending on the specific antibody. For example:

  • Sheep anti-human PGA5: 0.1 μg/mL

  • Mouse monoclonal anti-PGA5: 2-5 μg/mL

• Detection system: HRP-conjugated secondary antibodies at 1:50 to 1:5000 dilutions, followed by enhanced chemiluminescence detection .

• Buffer systems: Immunoblot Buffer Group 1 has been specifically validated for PGA5 detection .

What controls should be included when validating a new PGA5 antibody?

When validating a new PGA5 antibody, include the following controls:

• Positive tissue controls: Human stomach tissue or stomach cancer tissue lysates, which naturally express high levels of PGA5 .

• Recombinant protein control: Purified recombinant human PGA5 protein to confirm antibody specificity .

• Negative control tissues: Tissues known not to express PGA5 or with minimal expression.

• Peptide competition assay: Pre-incubation of the antibody with the immunizing peptide should abolish or significantly reduce the signal if the antibody is specific.

• Knockdown/knockout validation: If possible, samples from PGA5 knockdown or knockout models provide the strongest validation of antibody specificity.

• Isotype control: To assess non-specific binding, particularly for monoclonal antibodies (e.g., IgG1 isotype control for Clone 2C1) .

• Secondary antibody-only control: To rule out non-specific binding of the secondary antibody.

How do PGA5 antibodies perform in immunohistochemistry applications?

For immunohistochemistry applications with PGA5 antibodies:

• Fixation and processing: PGA5 antibodies generally work well with formalin-fixed, paraffin-embedded (FFPE) tissue sections .

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) is typically effective for unmasking PGA5 epitopes in FFPE sections.

• Antibody concentration: For monoclonal antibodies, concentrations of 0.5-30 μg/mL have been validated. Clone 974731 performed well at 0.5 μg/mL in human stomach sections , while other antibodies required higher concentrations (around 30 μg/mL) .

• Detection systems: Both DAB (3,3'-diaminobenzidine) chromogenic detection and fluorescent secondary antibodies have been validated. For enhanced sensitivity, polymer-based detection systems like Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody have proven effective .

• Incubation conditions: Room temperature incubation for 1 hour has been validated for many antibodies, though specific optimization may be required for each antibody clone .

• Expected staining pattern: Strong cytoplasmic staining in chief cells of the gastric mucosa, with minimal background in other cell types.

How should I interpret variations in PGA5 band size across different experiments?

Variations in PGA5 band size (ranging from 42-48 kDa in reports) can occur due to several factors:

• Post-translational modifications: PGA5 undergoes processing from its zymogen form to active enzyme, which can alter its molecular weight. Different tissue samples may contain varying proportions of these forms .

• Glycosylation status: Variable glycosylation patterns can cause apparent shifts in molecular weight.

• Experimental conditions: Different gel percentages, running buffers, and molecular weight markers can affect the apparent molecular weight.

• Antibody specificity: Different antibodies targeting distinct epitopes might recognize different forms or processing states of PGA5.

• Separation systems: The observed molecular weight of 48 kDa in Simple Western™ systems versus 45 kDa in traditional Western blot illustrates how detection platforms can influence apparent molecular weight .

When interpreting results, consider:

• Document the exact experimental conditions

• Use appropriate molecular weight markers

• Compare results to published literature for the specific antibody used

• Verify specificity with recombinant protein controls

How can I distinguish between different PGA isozymes (PGA3, PGA4, PGA5) when they share high sequence homology?

Distinguishing between highly homologous PGA isozymes requires careful antibody selection and validation strategies:

• Epitope-specific antibodies: Select antibodies raised against regions where amino acid differences exist between isozymes. For example, antibodies targeting the 2-4 amino acid residues that differ between PGA3, PGA4, and PGA5 .

• Immunoprecipitation followed by mass spectrometry: This approach can definitively identify which specific isozyme is being detected based on peptide sequences unique to each isozyme.

• 2D gel electrophoresis: Different PGA isozymes often have subtle differences in isoelectric points that can be resolved by 2D electrophoresis prior to immunoblotting.

• Recombinant protein standards: Run purified recombinant proteins of each isozyme as standards to compare migration patterns.

• Peptide competition assays: Using peptides specific to each isozyme can help determine antibody cross-reactivity.

• Expression profiling: Combine antibody detection with RT-PCR using isozyme-specific primers to correlate protein detection with mRNA expression patterns.

• Sequential immunodepletion: Deplete samples with antibodies specific to one isozyme before probing for others to assess potential cross-reactivity.

What are the recommended approaches for multiplexing PGA5 with other gastric biomarkers?

For multiplexing PGA5 with other gastric biomarkers:

• Antibody selection considerations:

  • Species compatibility: Choose primary antibodies raised in different host species to avoid cross-reactivity of secondary antibodies

  • Isotype differences: When using multiple mouse monoclonal antibodies, select different isotypes (IgG1, IgG2a, etc.) for isotype-specific secondary antibodies

• Immunofluorescence multiplexing strategies:

  • Sequential staining: Apply and detect one primary antibody before applying the next

  • Use directly conjugated primary antibodies: PGA5 antibodies conjugated to Alexa Fluor 647 or 750 can be combined with antibodies to other markers conjugated to different fluorophores

  • Tyramide signal amplification: For detecting low-abundance markers alongside PGA5

• Recommended gastric marker combinations:

  • PGA5 + Gastrin (G cells)

  • PGA5 + H+/K+ ATPase (parietal cells)

  • PGA5 + MUC5AC (surface mucous cells)

  • PGA5 + CDX2 (intestinal metaplasia marker)

• Western blot multiplexing:

  • Strip and reprobe membranes sequentially

  • Use differentially labeled secondary antibodies for simultaneous detection

  • Consider fluorescent Western blotting for quantitative multiplex analysis

• Validation controls:

  • Single-stained controls to assess bleed-through

  • Isotype controls for each primary antibody

  • Blocking peptide controls to confirm specificity

What are the critical considerations when using PGA5 antibodies for quantitative analysis of stomach cancer biomarkers?

When using PGA5 antibodies for quantitative analysis in stomach cancer research:

• Sample selection and processing:

  • Matched normal-tumor pairs from the same patient are ideal for comparative analysis

  • Standardized collection and processing protocols to minimize pre-analytical variables

  • Microdissection may be necessary to separate tumor cells from surrounding stroma

• Quantitative methodologies:

  • ELISA-based quantification: Use a standard curve with recombinant PGA5 protein

  • Western blot densitometry: Include loading controls and reference standards

  • Immunohistochemistry quantification: Use digital pathology platforms with validated algorithms for scoring

• Data normalization strategies:

  • For Western blots: Normalize to housekeeping proteins that remain stable in gastric cancer (β-actin may not be ideal; consider GAPDH or vinculin)

  • For IHC: Assess percentage of positive cells and staining intensity using standardized scoring systems

• Potential confounding factors:

  • H. pylori infection status can significantly affect PGA5 expression

  • Proton pump inhibitor use alters gastric physiology and may affect PGA5 levels

  • Tumor heterogeneity requires adequate sampling strategies

• Validation approaches:

  • Correlation with mRNA expression data

  • Comparison with other pepsinogen detection methods

  • Survival analysis to establish prognostic significance

• Technical considerations:

  • The Simple Western system detected PGA5 at 48 kDa in both normal stomach and stomach cancer tissue, suggesting consistent detection across pathological states

  • Higher antibody concentrations (20 μg/mL) may be required for cancer tissue samples compared to normal tissue (0.1 μg/mL)

How can I troubleshoot non-specific bands when using PGA5 antibodies in Western blot applications?

When encountering non-specific bands with PGA5 antibodies:

• Optimization of blocking conditions:

  • Test different blocking agents (5% non-fat milk, 5% BSA, commercial blockers)

  • Extend blocking time to 2-3 hours at room temperature or overnight at 4°C

  • Add 0.1-0.3% Tween-20 to reduce non-specific hydrophobic interactions

• Antibody dilution optimization:

  • Perform a dilution series (e.g., 1:500, 1:1000, 1:2000) to determine optimal concentration

  • For monoclonal antibodies, concentrations of 2-5 μg/mL have been validated

  • For polyclonal antibodies, higher dilutions may reduce non-specific binding

• Addressing cross-reactivity issues:

  • Pre-adsorb polyclonal antibodies with tissue lysates from negative control tissues

  • Use peptide competition assays to identify specific versus non-specific bands

  • Consider monoclonal antibodies with defined epitopes for higher specificity

• Sample preparation modifications:

  • Include additional protease inhibitors to prevent degradation products

  • Optimize lysis buffer composition (RIPA vs. NP-40 vs. Triton X-100)

  • Centrifuge lysates at high speed (>14,000 × g) to remove particulates

• Gel and transfer conditions:

  • Use freshly prepared buffers

  • Optimize transfer conditions (time, voltage, buffer composition)

  • Consider gradient gels for better separation

• PGA5-specific considerations:

  • Different molecular weight bands may represent different processing states of pepsinogen

  • Ascitic fluid-purified monoclonal antibodies may contain contaminating proteins; consider using protein A/G-purified antibodies

What experimental approaches can determine the functional significance of PGA5 expression changes in pathological conditions?

To investigate the functional significance of PGA5 expression changes:

• In vitro functional assays:

  • Enzymatic activity assays using synthetic peptide substrates to measure pepsin activity

  • pH-dependence studies to assess activation under different pH conditions

  • Inhibitor studies using pepstatin A to confirm specificity of activity

• Genetic manipulation approaches:

  • CRISPR/Cas9-mediated knockout of PGA5 in gastric cell lines

  • siRNA or shRNA knockdown for transient expression reduction

  • Overexpression studies using vectors containing the PGA5 coding sequence

• 3D organoid models:

  • Gastric organoids derived from normal and pathological tissues

  • Co-culture systems to study interactions with immune or stromal cells

  • Drug response assays in PGA5-manipulated organoids

• Correlation with clinical parameters:

  • Analysis of PGA5 expression levels in relation to:

    • Tumor stage and grade

    • Patient survival and treatment response

    • H. pylori infection status

    • Presence of atrophic gastritis or intestinal metaplasia

• Biomarker validation studies:

  • Longitudinal serum pepsinogen measurements in patients at risk for gastric cancer

  • Determination of PGA5:PGC ratios as indicators of gastric atrophy

  • Correlation of tissue expression with circulating levels

• Molecular interaction studies:

  • Co-immunoprecipitation to identify PGA5 binding partners

  • ChIP-seq to identify transcription factors regulating PGA5 expression

  • Pathway analysis following PGA5 manipulation

Why might PGA5 antibodies show inconsistent results between fresh and archived tissue samples?

Inconsistencies between fresh and archived samples may occur due to:

• Fixation-related epitope masking:

  • Formalin fixation can cross-link proteins and mask epitopes

  • Longer fixation times in archived samples may require more aggressive antigen retrieval

  • Solution: Optimize antigen retrieval methods (try citrate buffer pH 6.0, EDTA buffer pH 9.0, or enzymatic retrieval)

• Protein degradation in archived samples:

  • Storage conditions affect protein integrity

  • Older paraffin blocks may have undergone oxidative damage

  • Solution: Use antibodies targeting stable epitopes or multiple antibodies targeting different regions

• Processing differences:

  • Variations in tissue processing protocols between fresh and archived samples

  • Different fixatives used historically

  • Solution: Document processing methods and account for these variables in interpretation

• Antibody clone considerations:

  • Some clones perform better with fresh samples, others with fixed tissues

  • Monoclonal antibody Clone 974731 has been validated for FFPE tissues

  • Solution: Test multiple antibody clones if available

• Detection system compatibility:

  • Modern polymer-based detection systems may work differently with older samples

  • Solution: Validate detection systems with positive controls of similar age and processing

How can I quantitatively compare PGA5 expression across different experimental platforms?

For quantitative cross-platform comparison:

• Standardization approaches:

  • Include identical reference samples across all platforms

  • Use recombinant PGA5 protein standards at known concentrations

  • Develop normalization algorithms specific to each platform

• Platform-specific considerations:

  • Western blot: Use densitometry with standard curves of recombinant protein

  • ELISA: Establish standard curves with identical recombinant standards

  • IHC: Use digital image analysis with calibrated intensity measurements

  • Simple Western™: Utilize the Area measurement for comparative quantification

• Statistical methods for cross-platform normalization:

  • Z-score normalization across platforms

  • Quantile normalization for distribution matching

  • Use of multiple reference genes/proteins for normalization

• Validation strategies:

  • Measure the same samples on multiple platforms

  • Calculate correlation coefficients between platforms

  • Determine platform-specific correction factors

• Data integration approaches:

  • Meta-analysis techniques for combining data

  • Machine learning algorithms for cross-platform data integration

  • Bayesian methods to account for platform-specific biases

What are the best preservation methods for stomach tissue samples to maintain PGA5 immunoreactivity?

To maintain optimal PGA5 immunoreactivity in stomach tissue samples:

• Immediate post-collection handling:

  • Process tissues within 30 minutes of collection

  • Keep samples on ice if immediate processing is not possible

  • Avoid freeze-thaw cycles for fresh frozen samples

• Fixation protocols:

  • 10% neutral buffered formalin for 12-24 hours is optimal

  • Avoid overfixation, which can mask epitopes

  • Consider alternatives like zinc-based fixatives for certain applications

• Frozen tissue preservation:

  • Snap freezing in liquid nitrogen followed by storage at -80°C

  • Embedding in OCT compound before freezing

  • Use of RNAlater™ for samples intended for both protein and RNA analysis

• Paraffin embedding considerations:

  • Maintain temperatures below 60°C during embedding to prevent protein denaturation

  • Use high-quality paraffin with consistent formulation

  • Minimize exposure time to molten paraffin

• Long-term storage recommendations:

  • For FFPE blocks: Store at room temperature in low-humidity environment

  • For frozen sections: Maintain at -80°C with desiccant

  • For tissue lysates: Aliquot and store at -80°C with protease inhibitors

• Quality control measures:

  • Include timeline annotations for collection-to-preservation time

  • Document preservation method for each sample

  • Regularly test archived samples for antigen preservation

How can PGA5 antibodies be utilized in gastric cancer screening and prognosis research?

Applications of PGA5 antibodies in gastric cancer research include:

• Early detection biomarker development:

  • Immunohistochemical analysis of PGA5 in precancerous lesions

  • Correlation of tissue PGA5 expression patterns with serum pepsinogen levels

  • Development of multiplexed IHC panels combining PGA5 with other early markers

• Prognostic stratification approaches:

  • Quantitative assessment of PGA5 expression in tumor tissues

  • Correlation with clinical outcomes and survival data

  • Integration into prognostic algorithms with other molecular markers

• Monitoring treatment response:

  • Serial measurement of tissue PGA5 expression in biopsy samples

  • Correlation with endoscopic and radiological response criteria

  • Assessment of PGA5 as a surrogate marker for mucosal recovery

• Research applications:

  • Characterization of PGA5 expression in different molecular subtypes of gastric cancer

  • Investigation of PGA5 alterations in the cancer stem cell compartment

  • Analysis of PGA5 in the tumor microenvironment

• Technical approaches:

  • Tissue microarray analysis of large cohorts

  • Digital pathology quantification using validated algorithms

  • Single-cell analysis of PGA5 expression heterogeneity

What are the emerging techniques for studying PGA5 in the context of the gastric microbiome?

Emerging techniques for studying PGA5 in relation to the gastric microbiome:

• Spatial transcriptomics and proteomics:

  • Combining PGA5 antibody staining with in situ transcriptomics

  • Spatial proteomics to map PGA5 distribution relative to microbial niches

  • Digital spatial profiling for quantitative spatial analysis

• Microbiome-epithelial co-culture systems:

  • Gastric organoids co-cultured with defined microbial communities

  • PGA5 expression analysis following microbial manipulation

  • Assessment of microbial metabolite effects on PGA5 regulation

• In situ techniques for microbiome-protein interaction studies:

  • FISH combined with immunofluorescence for PGA5

  • Proximity ligation assays to detect PGA5-bacterial interactions

  • Live imaging of microbiome-epithelial interactions in ex vivo cultures

• Systems biology approaches:

  • Integration of proteomics, transcriptomics, and microbiome data

  • Network analysis of PGA5 in host-microbe interaction networks

  • Machine learning algorithms to identify microbial signatures associated with PGA5 alterations

• Human intervention studies:

  • Analysis of PGA5 expression before and after antibiotic treatment

  • Effects of probiotics or prebiotics on PGA5 regulation

  • H. pylori eradication effects on PGA5 expression patterns

How can PGA5 antibodies be incorporated into multi-omics studies of gastric physiology and pathology?

Integration of PGA5 antibodies into multi-omics research frameworks:

• Proteogenomic approaches:

  • Correlation of PGA5 protein levels (by immunoassays) with gene expression data

  • Integration with genomic alterations affecting the PGA gene cluster

  • Identification of post-transcriptional regulatory mechanisms

• Single-cell multi-omics integration:

  • Single-cell proteomics with PGA5 antibodies

  • Correlation with single-cell transcriptomics of the same populations

  • Spatial mapping of PGA5 expression in the tissue microenvironment

• Functional genomics validation:

  • CRISPR screens followed by PGA5 immunodetection

  • Validation of regulatory elements using PGA5 as a readout

  • Epigenetic profiling correlated with PGA5 expression patterns

• Clinical sample multi-omics:

  • Integration of tissue PGA5 IHC data with:

    • Genomic sequencing

    • Metabolomic profiles

    • Microbiome composition

    • Immune cell infiltration patterns

• Data integration and visualization approaches:

  • Multi-parameter visualization tools for integrated data analysis

  • Machine learning algorithms for pattern recognition

  • Network analysis incorporating PGA5 as a node in functional networks

By utilizing these approaches, researchers can gain a more comprehensive understanding of how PGA5 functions within the complex systems of gastric physiology and pathology, potentially leading to new diagnostic and therapeutic strategies for gastric diseases.

Human Pepsinogen A5/PGA5 Antibody